3D Medicines
Manufacturing · China · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Block B Tower 2 no. 158 Xinjunhuan Rd Pu...Phone Number
+86 18021007915Website
www.3dmedcare.comRevenue
$9.1 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
1
1
1
1
About 3D Medicines
3D Medicines is a clinical-stage biopharmaceutical company focused on the development of differentiated next-generation immuno-oncology drugs for cancer patients. The world's first subcutaneous injection PD-L1 antibody Envafolimab (KN035), is currently under clinical development in the United States, China and Japan. The company is building the company's pipeline targeting major indications through combination strategy, either with in-house assets or in collaboration with partners around the world. With a professional team in the China and US, 3D Medicines is capable of conducting global clinical development and registration.Explore more
3D Medicines Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is 3D Medicines your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when 3D Medicines launches new products
Funding: Get notified immidiatlly once 3D Medicines has new funding data
Earning: See what the market has to say on 3D Medicines recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at 3D Medicines
Click to see if 3D Medicines had a recent Job posting/layoffs
3D Medicines, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if 3D Medicines is spiking on competitors!
Check if 3D Medicines has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Reach out to Masked Content who joined 3D Medicines as Masked Content
Find 3 more new buyers
Company Profile Activity
Activity Insights
3D Medicines is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
3D Medicines is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about 3D Medicines.
3D Medicines financials insights
Gather financial insights about 3D Medicines, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2017
Private Equity
$101M
2020
Private Equity
$224M
3D Medicines Tech Stack
A closer look at the technologies used by 3D Medicines
Most Recent Scoops
Event
will be attending the Medlab Middle East 2023 conference as an exhibitor. The event will occur from February 6 to February 9, 2023.
Left Company
Executive Move
Executive Moves, Left Company
Event
will be attending the 2022 AACC Annual Scientific Meeting + Clinical Lab Expo conference as an exhibitor. The event will occur from July 24 to July 28, 2022.
Funding
Funding
3D Medicines News & Media
3D Medicines Inc. Appoints New Chief Commercial Officer - TipRanks.com
An update from 3D Medicines, Inc. ( ($HK:1244) ) is now available. 3D Medicines Inc. has announced the appointment of Mr. Ding Gan as the new Chief Commercial Offic...Glenmark, Jiangsu Alphamab Biopharmaceuticals and 3D Medicines announce the signing of a License Agreement for KN035 (Envafolimab) for Multiple Geographies around the World
Glenmark will be responsible for further developing, registering, and commercializing Envafolimab in India, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America. Jiangsu Alphamab and 3D Medicines will receive a low double digit Million US Dollar amount up to launch, additional triple digit Million US Dollar milestone payments based on sales performance across the length of the agreement, and a royalty fee of single-to-double-digits percentage according to the level of net sales.TRACON Pharmaceuticals Announces Acceptance of the Envafolimab (KN035) NDA by the NMPA in China that was Submitted by its Corporate Partners Alphamab Oncology and 3D Medicines
NDA was Submitted in November in the Indication of MSI-H/dMMR Cancer, Including Colorectal and Gastric Cancer NDA was Submitted in November in the Indication of MSI-H/dMMR Cancer, Including Colorectal and Gastric CancerTRACON Pharmaceuticals Announces Submission for Approval of Envafolimab (KN035) with the NMPA in China by its Corporate Partners Alphamab Oncology and 3D Medicines
Submission for Approval Filed in Indication of MSI-H/dMMR Cancer, Including Colorectal and Gastric Cancer Submission for Approval Filed in Indication of MSI-H/dMMR Cancer, Including Colorectal and Gastric Cancer
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding 3D Medicines
Sign Up For FreeTo access detailed company insights
3D Medicines is a clinical-stage biopharmaceutical company focused on the development of differentiated next-generation immuno-oncology drugs for cancer patients. The world's first subcutaneous injection PD-L1 antibody Envafolimab (KN035), is currently under clinical development in the United States, China and Japan. The company is building the com... Read More
